October 19, 2011 |
A prenatal blood test that can detect Down syndrome in a fetus in early pregnancy is now available to doctors in 20 U.S. cities, says the developer of the test, Sequenom Inc . The test is a milestone in prenatal testing because it's the first non-invasive way to detect trisomy 21, the most common cause of Down syndrome. Until now, women have had to undergo amniocentesis or chorionic villus sampling, both invasive tests, to detect Down syndrome. A more recent strategy was to combine ultrasound testing with blood tests, but that test required confirmation with amniocentesis or CVS. The blood test measures fetal DNA in the mother's bloodstream.
February 1, 2000 |
San Diego-based biotech company Sequenom Inc. (SQNM) priced 5.25 million shares Monday at $26, above the expected range of $23 to $25, raising $136.5 million. The shares will begin trading today on Nasdaq. Sequenom, whose products to analyze genes are used in clinical trials and to develop drugs, sold 250,000 more shares than expected.
February 9, 2000 |
The new biotech rush is on. Is it a prescription for disaster? With biotechnology stocks sizzling, start-ups are scrambling to get in on the action. According to Prudential Securities analyst Caroline Copithorne, 11 biotechs have filed already this year to make initial public offerings. That compares with 11 biotech companies for the entire 1999 calendar year. Genomics stocks have led the biotech sector's charge. Affymetrix Inc.
May 30, 2001 |
San Diego-based Sequenom Inc. said Tuesday it will buy Britain's Gemini Genomics for $228 million in stock, part of a wave of consolidation in the emerging genomics industry. Sequenom said the tie-up would combine its genotyping technology platform with Gemini's expertise in population genetics, expanding their potential for disease-gene discovery.
May 21, 2002 |
The annual meeting of the nation's cancer specialists, one of the largest and most closely watched medical gatherings of the year, often gives biotechnology stocks a fillip. Not this year. More bad news from ImClone Systems Inc., whose drug Erbitux failed in a mid-stage trial to halt or reverse the course of head and neck cancer, sent its shares tumbling $2.29, or 17%, to $11.12 on Monday.
January 23, 2002 |
J. Craig Venter, the maverick scientist whose drive to crack the human genome ignited one of the fiercest rivalries in modern science, resigned Tuesday from the company he helped launch, Celera Genomics. Venter's abrupt departure from the high-profile gene-mapping company prompted speculation that he left under pressure from Celera's parent, Applera Corp. No successor to Venter was named.